Open Access1ISG-010 The cost of lacking regulatory clarity for nanosimilars
Author(s) -
Beat Flühmann,
Stefan Mühlebach
Publication year - 2018
Publication title -
pubmed central
Language(s) - English
Resource type - Conference proceedings
DOI - 10.1136/ejhpharm-2018-eahpconf.10
Subject(s) - biosimilar , regulatory science , clarity , bioequivalence , directive , business , european union , public economics , risk analysis (engineering) , medicine , actuarial science , computer science , economics , pharmacology , international trade , chemistry , programming language , biochemistry , pathology , bioavailability
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom